



CHANGE LOG

| Published Date | Status | Section and Subsection Affected | Description of Change(s) |
|----------------|---------------------|-----------------------------------|---|
| 04/01/2024 | Revision + Addition | #4; SPECIAL CONSIDERATIONS | <ul style="list-style-type: none"> • Clarified administration route for intranasal naloxone to include pre-packaged nasal spray (1mg per nostril or 4mg/0.1mL IN depending on formulation available), excluding newborns • Added special considerations for newborns/neonates not to use higher dose pre-packaged nasal spray due to the potential risk to precipitate withdrawal |
| 07/01/2024 | Re-Date/Re-Sign | Not applicable | Not applicable |
| 10/01/2024 | Addition | #13; Special Considerations | <ul style="list-style-type: none"> • Added information on beta blocker overdose |